Dead tumor cells expressing infectious salmon anemia virus fusogenic protein favor antigen cross-priming in vitro
Author
dc.contributor.author
Morales, Jonathan
Author
dc.contributor.author
Barrera Avalos, Carlos
Author
dc.contributor.author
Castro, Carlos
Author
dc.contributor.author
Castillo, Stephanie
Author
dc.contributor.author
Barrientos, Claudio
Author
dc.contributor.author
Robles Planells, Claudia
Author
dc.contributor.author
López, Ximena
Author
dc.contributor.author
Torres, Ernesto
Author
dc.contributor.author
Montoya, Margarita
Author
dc.contributor.author
Cortez San Martin, Marcelo
Author
dc.contributor.author
Riquelme, Denise
Author
dc.contributor.author
Escobar Álvarez, Alejandro
Author
dc.contributor.author
Fernández, Ricardo
Author
dc.contributor.author
Imarai, Mónica
Author
dc.contributor.author
Sauma Mahaluf, Daniela
Author
dc.contributor.author
Rojo, Leonel E.
Author
dc.contributor.author
Leiva Salcedo, Elias
Author
dc.contributor.author
Acuña Castillo, Claudio
Admission date
dc.date.accessioned
2018-07-03T14:39:34Z
Available date
dc.date.available
2018-07-03T14:39:34Z
Publication date
dc.date.issued
2017
Cita de ítem
dc.identifier.citation
Front. Immunol. 8:1170
es_ES
Identifier
dc.identifier.other
10.3389/fimmu.2017.01170
Identifier
dc.identifier.uri
https://repositorio.uchile.cl/handle/2250/149413
Abstract
dc.description.abstract
Antigen cross-presentation is a crucial step in the assembly of an antitumor immune response leading to activation of naive CD8 T cells. This process has been extensively used in clinical trials, in which dendritic cells generated in vitro are loaded with tumor antigens and then autotransplanted to the patients. Recently, the use of autologous transplant of dendritic cells fused with dying tumor cells has demonstrated good results in clinical studies. In this work, we generated a similar process in vivo by treating mice with dead tumor cells [cell bodies (CBs)] expressing the fusogenic protein of the infectious salmon anemia virus (ISAV). ISAV fusion protein retains its fusogenic capability when is expressed on mammalian cells in vitro and the CBs expressing it facilitates DCs maturation, antigen transfer by antigen-presenting cells, and increase cross-presentation by DCs in vitro. Additionally, we observed in the melanoma model that CBs with or without ISAV fusion protein reduce tumor growth in prophylactic treatment; however, only ISAV expressing CBs showed an increase CD4 and CD8 cells in spleen. Overall, our results suggest that CBs could be used as a complement with other type of strategies to amplify antitumor immune response.